Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review

吉西他滨 奥沙利铂 养生 顺铂 医学 内科学 肿瘤科 化疗 胃肠病学 癌症 结直肠癌
作者
Frédéric Fiteni,Thierry Nguyen,Déwi Vernerey,Marie‐Justine Paillard,Stefano Chong Hun Kim,Martin Demarchi,F. Fein,Christophe Borg,Franck Bonnetain,Xavier B. Pivot
出处
期刊:Cancer Medicine [Wiley]
卷期号:3 (6): 1502-1511 被引量:84
标识
DOI:10.1002/cam4.299
摘要

Cisplatin/gemcitabine association has been a standard of care for first-line regimen in advanced biliary tract cancer nevertheless oxaliplatin/gemcitabine regimen is frequently preferred. Because comparative effectiveness in clinical outcomes of cisplatin- versus oxaliplatin-containing chemotherapy is not available, a systematic review of studies assessing cisplatin/gemcitabine or oxaliplatin/gemcitabine chemotherapies in advanced biliary tract cancer was performed. Published studies evaluating cisplatin/gemcitabine or oxaliplatin/gemcitabine in advanced biliary tract cancer were included. Each study was weighted according to the number of patients included. The primary objective was to assess weighted median of medians overall survival (mOS) reported for both regimens. Secondary goals were to assess weighted median of medians progression-free survival (mPFS) and toxic effects were pooled and compared within each arm. Thirty-three studies involving 1470 patients were analyzed. In total, 771 and 699 patients were treated by cisplatin/gemcitabine and oxaliplatin/gemcitabine, respectively. Weighted median of mOS was 9.7 months in cisplatin group and 9.5 months in oxaliplatin group. Cisplatin-based chemotherapy was significantly associated with more grade 3 and 4 asthenia, diarrhea, liver toxicity, and hematological toxicity. Sensitivity analysis including only the studies with the standard regimen of cisplatin (25-35 mg/m(2) administered on days 1 and 8) showed that the weighted median of mOS increased from 9.7 to 11.7 months but Gem/CDDP regimen remained more toxic than Gemox regimen. These results suggest that the Gem/CDDP regimen with cisplatin (25-35 mg/m(2)) administered on days 1 and 8 is associated with survival advantage than Gemox regimen but with addition of toxicity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
li完成签到,获得积分10
1秒前
1秒前
木子发布了新的文献求助10
2秒前
钟嘉霖完成签到,获得积分10
2秒前
小小发布了新的文献求助100
3秒前
Maestro_S的应助被Kenny采纳,获得10
3秒前
天际小山完成签到,获得积分10
5秒前
5秒前
xing发布了新的文献求助10
5秒前
6秒前
丁鹏笑完成签到 ,获得积分0
6秒前
孟昊如完成签到,获得积分10
6秒前
null的应助被aaa采纳,获得10
7秒前
8秒前
10秒前
英姑的应助被aoa采纳,获得10
11秒前
12秒前
12秒前
清汐完成签到 ,获得积分10
12秒前
那当然完成签到 ,获得积分10
13秒前
13秒前
苗浩阳完成签到,获得积分10
15秒前
Shirley发布了新的文献求助10
16秒前
ChaseY完成签到 ,获得积分10
17秒前
xing发布了新的文献求助10
17秒前
科目三的应助被sinmon采纳,获得10
18秒前
WK完成签到,获得积分10
18秒前
19秒前
执着的青烟完成签到,获得积分10
19秒前
19秒前
19秒前
ice完成签到 ,获得积分10
20秒前
舔舔给舔舔的求助进行了留言
20秒前
21秒前
21秒前
22秒前
22秒前
Owen的应助被aaa采纳,获得30
22秒前
casual完成签到,获得积分10
23秒前
树袋熊完成签到,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160961
求助须知:如何正确求助?哪些是违规求助? 9555819
关于积分的说明 21730291
捐赠科研通 7750940
什么是DOI,文献DOI怎么找? 3427477
关于科研通互助平台的介绍 2552515
邀请新用户注册赠送积分活动 2471912